Welcome to our dedicated page for Envveno Medical news (Ticker: NVNO), a resource for investors and traders seeking the latest updates and insights on Envveno Medical stock.
enVVeno Medical Corporation develops bioprosthetic venous valve devices for severe deep chronic venous insufficiency in the United States. News about NVNO centers on the company’s enVVe System, a minimally invasive transcatheter replacement venous valve, and its TAVVE pivotal study under FDA investigational device exemption approval.
Recurring updates also cover the VenoValve surgical replacement venous valve, FDA communications tied to device review, clinical-development planning, cash runway and operating losses, Nasdaq listing compliance, shareholder-approved capital-structure actions such as the reverse stock split, and investor communications from this late clinical-stage medical device issuer.
enVVeno Medical (NASDAQ: NVNO) announced that CEO Robert Berman participated in a Virtual Investor “What This Means” segment to discuss two recent milestones for the company’s enVVe replacement venous valve system. He highlighted the issuance of the first U.S. patent covering the enVVe system, which expands enVVeno Medical’s intellectual property portfolio.
Berman also discussed the company’s progress with what he described as the first FDA-approved pivotal trial for a non-surgical replacement venous valve targeting deep chronic venous insufficiency. According to enVVeno Medical, these milestones are intended to form key elements of its strategy to build shareholder value, strengthen its long-term competitive position, and reinforce barriers to entry around its technology. The company further stated that it views the replacement venous valve space as a large, untapped commercial opportunity and believes enVVe has the potential to transform the treatment paradigm. The Virtual Investor segment is now available online.
enVVeno Medical (NASDAQ:NVNO) received U.S. Patent No. 12,575,932 covering core components of its enVVe transcatheter replacement venous valve system, including valve, support frame, crimping, and delivery systems.
The patent, combined with prior FDA IDE approval for the TAVVE pivotal trial, supports clinical advancement and potential future commercialization targeting deep venous insufficiency.
enVVeno Medical (NASDAQ:NVNO) will present in the Webull Corporate Connect Webinar Series, held virtually June 24‑25, 2026. CEO Rob Berman will speak on June 24, 2026 from 2:00–2:20 PM ET, covering the company’s deep venous disease focus, recent FDA IDE approval for the enVVe® System, and plans for a first U.S. pivotal trial of a non-surgical replacement venous valve.
enVVeno Medical (Nasdaq: NVNO) announced that CEO Robert Berman will participate in a Virtual Investor Closing Bell event on June 9, 2026, at 4:00 PM ET.
He will discuss the recently reported FDA IDE approval for the enVVe System and host a live Q&A, with webcast and 90-day replay on the company website.
enVVeno Medical (Nasdaq: NVNO) highlighted the U.S. Food and Drug Administration's first-ever IDE approval for a U.S. pivotal study of a non-surgical replacement venous valve. The IDE positions the company to advance a potential first effective treatment option for about 3 million U.S. patients suffering from DVI.
CEO Robert Berman discussed the implications in a Virtual Investor "What This Means" segment, which is now available for viewing.
enVVeno Medical (NASDAQ:NVNO) reported Q1 2026 results and a business update highlighting FDA IDE approval for the TAVVE U.S. pivotal study of the enVVe System. Cash and investments were approximately $24.9M as of March 31, 2026, with an expected runway into Q3 2027. The company expects increased cash burn as it prepares to start patient enrollment later in 2026.
enVVeno Medical (NASDAQ:NVNO) received the first-ever FDA IDE approval to begin a U.S. pivotal study (TAVVE) of its minimally invasive enVVe system, a non-surgical replacement venous valve for severe deep Chronic Venous Insufficiency (CVI). Clinical site activation and enrollment are expected later in 2026. The company cites an addressable U.S. population of ~3 million patients and a potential multi-billion-dollar market. enVVeno reported approximately $25 million in cash and investments, funding operations into Q3 2027.
enVVeno Medical (NASDAQ:NVNO) reported full-year 2025 results and strategic progress on its next‑generation enVVe System. Pre-clinical development is complete and the company is in active FDA discussions to initiate a pivotal trial in 2026. Cash and investments were $28.2M at year-end, with an expected 2026 burn of $4–5M per quarter, providing runway into mid‑2027 if key clinical milestones are met. 2025 net loss narrowed to $19.5M from $21.8M in 2024; R&D expense was $10.0M (down 19%), and SG&A was $10.9M.
enVVeno Medical (NASDAQ:NVNO) regained compliance with Nasdaq Listing Rule 5550(a)(2) after its common stock maintained a closing bid of at least $1.00 for 10 consecutive business days, from January 20, 2026 through February 2, 2026. Nasdaq confirmed the matter is closed.
The company reported year-end cash and investments of approximately $28 million as of December 31, 2025 and said it has made meaningful progress on its 2026 strategic plans, with additional details expected in the coming weeks.
enVVeno Medical (NASDAQ:NVNO) announced a reverse stock split at a 1-for-35 ratio, effective 12:01 a.m. ET on January 20, 2026. Post-split trading on The Nasdaq Capital Market under the existing symbol NVNO will begin on January 20, 2026, and the company will use a new CUSIP 29415J205.
Shareholders approved the Reverse Stock Split at the annual meeting on December 11, 2025. The split will combine every 35 pre-split shares into one post-split share, reducing outstanding common stock from approximately 22.9 million to approximately 655 thousand. No fractional shares will be issued; cash will be paid in lieu of fractions. Equity awards and warrants will be adjusted accordingly.